Genetic Association Between Gene Polymorphisms and Risk of Prostate Cancer: A Meta-Analysis

Overview

Journal Front Physiol

Date 2017 Dec 19

PMID 29249982

Citations 4

Authors

Hong Weng

Xian-Tao Zeng

Xing-Huan Wang

Tong-Zu Liu

Da-Lin He

Affiliations

Soon will be listed here.

Abstract

Studies suggests that ()-1306 C/T and -1607 1G/2G polymorphisms affect the risk of prostate cancer. However, the conclusions remain controversial and no pooled evidence of this topic has been published. Therefore, we aimed to perform a meta-analysis to shed some light on the controversial conclusion pertaining to the associations of -1306 C/T and -1607 1G/2G polymorphisms with prostate cancer susceptibility. A thorough literature search was performed up to August, 2016 with the PubMed, EMBASE, CBM, CNKI, and Wanfang databases. Odds ratios (ORs) and corresponding 95% confidence intervals (95% CIs) were calculated to address the correlations between these polymorphisms and risk of prostate cancer. The meta-analysis included six studies (1,921 patients and 1,988 controls) on -1306 C/T polymorphism and three studies on -1607 1G/2G polymorphism (438 patients and 394 controls), respectively. The overall results of meta-analysis showed that an elevated risk of the disease was implicated in -1306 C/T polymorphism under two genetic models (CT vs. CC: OR = 1.78, 95% CI = 1.33-2.38; TT+CT vs. CC: OR = 1.62, 95% CI = 1.24-2.12) and no significant association was observed between -1607 1G/2G polymorphism and the risk of prostate cancer. The subgroup analysis results of -1306 C/T polymorphism were similar to the overall results. However, decreased risk of prostate cancer was observed in the Caucasians for -1607 1G/2G polymorphism. Current meta-analysis indicates that -1306 C/T polymorphism is associated with elevated risk of prostate cancer, but -1607 1G/2G polymorphism may inhibit the occurrence of prostate cancer in Caucasians. Further studies are warranted to verify the conclusions.

Citing Articles

Serum Matrix Metalloproteinases and Risk of Urologic Cancers: A Bidirectional Mendelian Randomization Study.

Yang B, Zeng X, Wang H, Feng J, Hou S Am J Mens Health. 2025; 19(1):15579883241311229.

PMID: 39930792 PMC: 11811975. DOI: 10.1177/15579883241311229.

Current evidence on the relationships among five polymorphisms in the matrix metalloproteinases genes and prostate cancer risk.

Gui J, Zhou H, Li S, Chen A, Liu Q, Zhu L Sci Rep. 2024; 14(1):11355.

PMID: 38762659 PMC: 11102503. DOI: 10.1038/s41598-024-62016-z.

Lack of association between matrix metalloproteinase-1 gene rs1799750 polymorphism and osteoarthritis susceptibility: a meta-analysis.

Peng L, Bin J, Ou Y, Zhu L, Lu J Biosci Rep. 2019; 39(4).

PMID: 30886066 PMC: 6465197. DOI: 10.1042/BSR20181960.

Letter to the editor regarding the publication "Association between matrix-metalloproteinase polymorphisms and prostate cancer risk: a meta-analysis and systematic review".

Jayaraj R, Kumarasamy C Cancer Manag Res. 2019; 11:1067-1068.

PMID: 30774434 PMC: 6353026. DOI: 10.2147/CMAR.S195169.

Association between matrix-metalloproteinase polymorphisms and prostate cancer risk: a meta-analysis and systematic review.

Zhou H, Zhu X Cancer Manag Res. 2018; 10:5247-5259.

PMID: 30464622 PMC: 6223342. DOI: 10.2147/CMAR.S177551.

References

Yaykasli K, Kayikci M, Yamak N, Soguktas H, Duzenli S, Arslan A . Polymorphisms in MMP-2 and TIMP-2 in Turkish patients with prostate cancer. Turk J Med Sci. 2014; 44(5):839-43. View

Adabi Z, Mohsen Ziaei S, Imani M, Samzadeh M, Narouie B, Jamaldini S . Genetic Polymorphism of MMP2 Gene and Susceptibility to Prostate Cancer. Arch Med Res. 2015; 46(7):546-50. DOI: 10.1016/j.arcmed.2015.08.004. View

Shajarehpoor Salavati L, Tafvizi F, Manjili H . The association between MMP2 -1306 C > T (rs243865) polymorphism and risk of prostate cancer. Ir J Med Sci. 2016; 186(1):103-111. DOI: 10.1007/s11845-016-1492-9. View

Thakkinstian A, McElduff P, DEste C, Duffy D, Attia J . A method for meta-analysis of molecular association studies. Stat Med. 2004; 24(9):1291-306. DOI: 10.1002/sim.2010. View

Tsuchiya N, Narita S, Kumazawa T, Inoue T, Ma Z, Tsuruta H . Clinical significance of a single nucleotide polymorphism and allelic imbalance of matrix metalloproteinase-1 promoter region in prostate cancer. Oncol Rep. 2009; 22(3):493-9. DOI: 10.3892/or_00000462. View

Yan C, Boyd D . Regulation of matrix metalloproteinase gene expression. J Cell Physiol. 2006; 211(1):19-26. DOI: 10.1002/jcp.20948. View

Yan Y, Weng H, Shen Z, Wu L, Zeng X . Association between interleukin-4 gene -590 c/t, -33 c/t, and 70-base-pair polymorphisms and periodontitis susceptibility: a meta-analysis. J Periodontol. 2014; 85(11):e354-62. DOI: 10.1902/jop.2014.140317. View

Moher D, Liberati A, Tetzlaff J, Altman D . Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol. 2009; 62(10):1006-12. DOI: 10.1016/j.jclinepi.2009.06.005. View

Zeng X, Yao Q, Weng H, Li S, Huang J, Wang X . Meta-analysis of vitamin D receptor gene polymorphisms and benign prostatic hyperplasia risk. Mol Biol Rep. 2014; 41(10):6713-7. DOI: 10.1007/s11033-014-3554-2. View

10.

Srivastava P, Lone T, Kapoor R, Mittal R . Association of promoter polymorphisms in MMP2 and TIMP2 with prostate cancer susceptibility in North India. Arch Med Res. 2012; 43(2):117-24. DOI: 10.1016/j.arcmed.2012.02.006. View

11.

Jacobs E, Hsing A, Bain E, Stevens V, Wang Y, Chen J . Polymorphisms in angiogenesis-related genes and prostate cancer. Cancer Epidemiol Biomarkers Prev. 2008; 17(4):972-7. DOI: 10.1158/1055-9965.EPI-07-2787. View

12.

Sissung T, Price D, Del Re M, Ley A, Giovannetti E, Figg W . Genetic variation: effect on prostate cancer. Biochim Biophys Acta. 2014; 1846(2):446-56. PMC: 4260983. DOI: 10.1016/j.bbcan.2014.08.007. View

13.

Chen W, Zheng R, Baade P, Zhang S, Zeng H, Bray F . Cancer statistics in China, 2015. CA Cancer J Clin. 2016; 66(2):115-32. DOI: 10.3322/caac.21338. View

14.

Albayrak S, Canguven O, Goktas C, Aydemir H, Koksal V . Role of MMP-1 1G/2G promoter gene polymorphism on the development of prostate cancer in the Turkish population. Urol Int. 2007; 79(4):312-5. DOI: 10.1159/000109715. View

15.

Reis S, Pontes Jr J, Villanova F, Borra P, Antunes A, DallOglio M . Genetic polymorphisms of matrix metalloproteinases: susceptibility and prognostic implications for prostate cancer. J Urol. 2009; 181(5):2320-5. DOI: 10.1016/j.juro.2009.01.012. View

16.

Schleutker J . Polymorphisms in androgen signaling pathway predisposing to prostate cancer. Mol Cell Endocrinol. 2011; 360(1-2):25-37. DOI: 10.1016/j.mce.2011.07.007. View

17.

Haas G, Sakr W . Epidemiology of prostate cancer. CA Cancer J Clin. 1997; 47(5):273-87. DOI: 10.3322/canjclin.47.5.273. View

18.

Torre L, Bray F, Siegel R, Ferlay J, Lortet-Tieulent J, Jemal A . Global cancer statistics, 2012. CA Cancer J Clin. 2015; 65(2):87-108. DOI: 10.3322/caac.21262. View

19.

Ito K . Prostate cancer in Asian men. Nat Rev Urol. 2014; 11(4):197-212. DOI: 10.1038/nrurol.2014.42. View

20.

Weng H, Yan Y, Jin Y, Meng X, Mo Y, Zeng X . Matrix metalloproteinase gene polymorphisms and periodontitis susceptibility: a meta-analysis involving 6,162 individuals. Sci Rep. 2016; 6:24812. PMC: 4837403. DOI: 10.1038/srep24812. View